CAMBRIDGE, UK–(Business Wire)–PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, is pleased to confirm that its PROFILE trial has reached the half way mark in...
The study aims to: Evaluate the safety of alfapump DSR in patients with heart failure Assess the feasibility of alfapump DSR to remove excess sodium and fluid from the body Explore the potential impact of DSR therapy to restore response to diuretics Ghent, BELGIUM – 7...
AL101 is the company’s second product candidate designed to increase the level of progranulin in the human brain. Progranulin has been identified as a key regulator of microglial function in the brain with strong genetic links to multiple neurodegenerative disorders....
SUZHOU, China and CAMBRIDGE, Mass., Jan. 6, 2020 /PRNewswire/ — CStone Pharmaceuticals (“CStone”, HKEX: 2616), a biopharmaceutical company focused on developing and commercializing immuno-oncology and precision medicines, and Blueprint Medicines...
NEW YORK and VIENNA, Austria, Jan. 06, 2020 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today...
SALT LAKE CITY, Jan. 06, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new analysis of the GUIDED1 clinical trial using the 6-item...
Email
Text